Follow the people · Insider
Harold H. Shlevin
Harold H. Shlevin files insider transactions with the SEC as a chief executive officer of Galectin Therapeutics (GALT). We hold 2 disclosed purchases and sales filed since 29 August 2012, 2 of them in the last 90 days.
- Files forGALT
- Disclosed buys and sells2 in all, 2 in the last 90 days
- Last disclosure30 June 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 27 August 2012 — 29 June 2026Chief Executive Officer · Galectin Therapeutics (GALT)105 Form 4 lines · source: SEC Form 4
Everything they disclosed
105 entries, newest first — one per disclosure report, one per Form 4 line- exercised options over 7,732 shares of Galectin TherapeuticsSEC Form 430 June 2026Common Stock · traded 26 June 2026 · filed 30 June 2026
- ▼ sold on the open market 7,732 shares of Galectin TherapeuticsSEC Form 430 June 2026Common Stock · traded 26 June 2026 · filed 30 June 2026
- exercised options over 22,268 shares of Galectin TherapeuticsSEC Form 430 June 2026Common Stock · traded 29 June 2026 · filed 30 June 2026
- ▼ sold on the open market 22,268 shares of Galectin TherapeuticsSEC Form 430 June 2026Common Stock · traded 29 June 2026 · filed 30 June 2026
- exercised options over 7,732 shares of Galectin Therapeutics (a derivative holding)SEC Form 430 June 2026Stock Option (right to buy) · traded 26 June 2026 · filed 30 June 2026
- exercised options over 22,268 shares of Galectin Therapeutics (a derivative holding)SEC Form 430 June 2026Stock Option (right to buy) · traded 29 June 2026 · filed 30 June 2026
- was granted 60,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 421 January 2026Stock option (right to buy) · traded 16 January 2026 · filed 21 January 2026
- was granted 60,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 421 January 2026Stock option (right to buy) · traded 16 January 2026 · filed 21 January 2026
- exercised options over 20,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 419 December 2025Stock Option (right to buy) · traded 17 December 2025 · filed 19 December 2025
- exercised options over 20,000 shares of Galectin TherapeuticsSEC Form 419 December 2025Common Stock · traded 17 December 2025 · filed 19 December 2025
- ▼ sold on the open market 19,793 shares of Galectin TherapeuticsSEC Form 419 December 2025Common Stock · traded 17 December 2025 · filed 19 December 2025
- ▼ sold on the open market 4,706 shares of Galectin TherapeuticsSEC Form 419 December 2025Common Stock · traded 17 December 2025 · filed 19 December 2025
- exercised options over 19,793 shares of Galectin Therapeutics (a derivative holding)SEC Form 416 December 2025Stock Option (right to buy) · traded 12 December 2025 · filed 16 December 2025
- exercised options over 8,417 shares of Galectin Therapeutics (a derivative holding)SEC Form 416 December 2025Stock option (right to buy) · traded 15 December 2025 · filed 16 December 2025
- exercised options over 19,793 shares of Galectin TherapeuticsSEC Form 416 December 2025Common Stock · traded 12 December 2025 · filed 16 December 2025
- ▼ sold on the open market 19,793 shares of Galectin TherapeuticsSEC Form 416 December 2025Common Stock · traded 12 December 2025 · filed 16 December 2025
- exercised options over 8,417 shares of Galectin TherapeuticsSEC Form 416 December 2025Common Stok · traded 15 December 2025 · filed 16 December 2025
- ▼ sold on the open market 8,417 shares of Galectin TherapeuticsSEC Form 416 December 2025Common Stock · traded 15 December 2025 · filed 16 December 2025
- exercised options over 35,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 410 December 2025Stock option (right to buy) · traded 8 December 2025 · filed 10 December 2025
- exercised options over 20,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 410 December 2025Stock option (right to buy) · traded 8 December 2025 · filed 10 December 2025
- exercised options over 20,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 410 December 2025Stock option (right to buy) · traded 8 December 2025 · filed 10 December 2025
- exercised options over 25,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 410 December 2025Stock Option (right to buy) · traded 8 December 2025 · filed 10 December 2025
- exercised options over 35,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 410 December 2025Stock Option (right to buy) · traded 8 December 2025 · filed 10 December 2025
- exercised options over 20,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 410 December 2025Stock Option (right to buy) · traded 8 December 2025 · filed 10 December 2025
- exercised options over 16,790 shares of Galectin Therapeutics (a derivative holding)SEC Form 410 December 2025Stock Option (right to buy) · traded 9 December 2025 · filed 10 December 2025
- ▼ sold on the open market 4,000 shares of Galectin TherapeuticsSEC Form 410 December 2025Common Stock · traded 8 December 2025 · filed 10 December 2025
- exercised options over 35,000 shares of Galectin TherapeuticsSEC Form 410 December 2025Common Stock · traded 8 December 2025 · filed 10 December 2025
- ▼ sold on the open market 35,000 shares of Galectin TherapeuticsSEC Form 410 December 2025Common Stock · traded 8 December 2025 · filed 10 December 2025
- exercised options over 20,000 shares of Galectin TherapeuticsSEC Form 410 December 2025Common Stock · traded 8 December 2025 · filed 10 December 2025
- ▼ sold on the open market 20,000 shares of Galectin TherapeuticsSEC Form 410 December 2025Common Stock · traded 8 December 2025 · filed 10 December 2025
- exercised options over 20,000 shares of Galectin TherapeuticsSEC Form 410 December 2025Common stock · traded 8 December 2025 · filed 10 December 2025
- ▼ sold on the open market 20,000 shares of Galectin TherapeuticsSEC Form 410 December 2025Common stock · traded 8 December 2025 · filed 10 December 2025
- exercised options over 25,000 shares of Galectin TherapeuticsSEC Form 410 December 2025Common Stock · traded 8 December 2025 · filed 10 December 2025
- ▼ sold on the open market 25,000 shares of Galectin TherapeuticsSEC Form 410 December 2025Common Stock · traded 8 December 2025 · filed 10 December 2025
- exercised options over 35,000 shares of Galectin TherapeuticsSEC Form 410 December 2025Common Stock · traded 8 December 2025 · filed 10 December 2025
- ▼ sold on the open market 35,000 shares of Galectin TherapeuticsSEC Form 410 December 2025Common Stock · traded 8 December 2025 · filed 10 December 2025
- exercised options over 20,000 shares of Galectin TherapeuticsSEC Form 410 December 2025Common Stock · traded 8 December 2025 · filed 10 December 2025
- ▼ sold on the open market 20,000 shares of Galectin TherapeuticsSEC Form 410 December 2025Common Stock · traded 8 December 2025 · filed 10 December 2025
- exercised options over 16,790 shares of Galectin TherapeuticsSEC Form 410 December 2025Common Stock · traded 9 December 2025 · filed 10 December 2025
- ▼ sold on the open market 16,790 shares of Galectin TherapeuticsSEC Form 410 December 2025Common Stock · traded 9 December 2025 · filed 10 December 2025
- was granted 60,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 430 January 2025Stock Option (right to buy) · traded 23 January 2025 · filed 30 January 2025
- ▲ bought on the open market 6,500 shares of Galectin TherapeuticsSEC Form 431 December 2024Common Stock · traded 30 December 2024 · filed 31 December 2024
- was granted 40,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 430 January 2023Stock Option (right to buy) · traded 26 January 2023 · filed 30 January 2023
- was granted 40,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 425 January 2022Stock Option (right to buy) · traded 24 January 2022 · filed 25 January 2022
- was granted 40,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 429 March 2021Stock option (right to buy) · traded 25 March 2021 · filed 29 March 2021
- was granted 70,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 429 March 2021Stock option (right to buy) · traded 25 March 2021 · filed 29 March 2021
- was granted 70,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 413 January 2020Stock option (right to buy) · traded 9 January 2020 · filed 13 January 2020
- exercised options over 8,706 shares of Galectin Therapeutics (a derivative holding)SEC Form 45 June 2019Stock option (right to buy) · traded 4 June 2019 · filed 5 June 2019
- exercised options over 8,706 shares of Galectin TherapeuticsSEC Form 45 June 2019Common Stock · traded 4 June 2019 · filed 5 June 2019
- was granted 70,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 418 January 2019Stock option (right to buy) · traded 16 January 2019 · filed 18 January 2019
- was granted 35,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 418 June 2018Stock option (right to buy) · traded 8 June 2018 · filed 18 June 2018
- exercised options over 25,544 shares of Galectin Therapeutics (a derivative holding)SEC Form 414 June 2018Stock option (right to buy) · traded 13 June 2018 · filed 14 June 2018
- ▼ sold on the open market 12,780 shares of Galectin TherapeuticsSEC Form 414 June 2018Common Stock · traded 12 June 2018 · filed 14 June 2018
- exercised options over 25,544 shares of Galectin TherapeuticsSEC Form 414 June 2018Common Stock · traded 13 June 2018 · filed 14 June 2018
- ▼ sold on the open market 30,918 shares of Galectin TherapeuticsSEC Form 414 June 2018Common Stock · traded 13 June 2018 · filed 14 June 2018
- exercised options over 50,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 412 June 2018Stock option (right to buy) · traded 8 June 2018 · filed 12 June 2018
- exercised options over 29,294 shares of Galectin Therapeutics (a derivative holding)SEC Form 412 June 2018Stock option (right to buy) · traded 8 June 2018 · filed 12 June 2018
- exercised options over 50,000 shares of Galectin TherapeuticsSEC Form 412 June 2018Common Stock · traded 8 June 2018 · filed 12 June 2018
- exercised options over 29,294 shares of Galectin TherapeuticsSEC Form 412 June 2018Common Stock · traded 8 June 2018 · filed 12 June 2018
- ▼ sold on the open market 104,294 shares of Galectin TherapeuticsSEC Form 412 June 2018Common Stock · traded 8 June 2018 · filed 12 June 2018
- ▼ sold on the open market 10,760 shares of Galectin TherapeuticsSEC Form 412 June 2018Common Stock · traded 11 June 2018 · filed 12 June 2018
- exercised options over 4,180 shares of Galectin Therapeutics (a derivative holding)SEC Form 48 June 2018Stock option (right to buy) · traded 6 June 2018 · filed 8 June 2018
- exercised options over 4,898 shares of Galectin Therapeutics (a derivative holding)SEC Form 48 June 2018Stock option (right to buy) · traded 6 June 2018 · filed 8 June 2018
- exercised options over 75,190 shares of Galectin Therapeutics (a derivative holding)SEC Form 48 June 2018Stock option (right to buy) · traded 7 June 2018 · filed 8 June 2018
- exercised options over 25,701 shares of Galectin Therapeutics (a derivative holding)SEC Form 48 June 2018Stock option (right to buy) · traded 7 June 2018 · filed 8 June 2018
- exercised options over 4,180 shares of Galectin TherapeuticsSEC Form 48 June 2018Common Stock · traded 6 June 2018 · filed 8 June 2018
- exercised options over 4,898 shares of Galectin TherapeuticsSEC Form 48 June 2018Common Stock · traded 6 June 2018 · filed 8 June 2018
- ▼ sold on the open market 9,078 shares of Galectin TherapeuticsSEC Form 48 June 2018Common Stock · traded 6 June 2018 · filed 8 June 2018
- exercised options over 75,190 shares of Galectin TherapeuticsSEC Form 48 June 2018Common Stock · traded 7 June 2018 · filed 8 June 2018
- exercised options over 25,701 shares of Galectin TherapeuticsSEC Form 48 June 2018Common Stock · traded 7 June 2018 · filed 8 June 2018
- ▼ sold on the open market 100,891 shares of Galectin TherapeuticsSEC Form 48 June 2018Common Stock · traded 7 June 2018 · filed 8 June 2018
- exercised options over 5,500 shares of Galectin TherapeuticsSEC Form 46 June 2018Common Stock · traded 4 June 2018 · filed 6 June 2018
- exercised options over 5,407 shares of Galectin TherapeuticsSEC Form 46 June 2018Common Stock · traded 4 June 2018 · filed 6 June 2018
- ▼ sold on the open market 10,907 shares of Galectin TherapeuticsSEC Form 46 June 2018Common Stock · traded 4 June 2018 · filed 6 June 2018
- exercised options over 5,630 shares of Galectin TherapeuticsSEC Form 46 June 2018Common Stock · traded 5 June 2018 · filed 6 June 2018
- exercised options over 4,294 shares of Galectin TherapeuticsSEC Form 46 June 2018Common Stock · traded 5 June 2018 · filed 6 June 2018
- ▼ sold on the open market 9,924 shares of Galectin TherapeuticsSEC Form 46 June 2018Common Stock · traded 5 June 2018 · filed 6 June 2018
- exercised options over 5,500 shares of Galectin Therapeutics (a derivative holding)SEC Form 46 June 2018Stock option (right to buy) · traded 4 June 2018 · filed 6 June 2018
- exercised options over 5,407 shares of Galectin Therapeutics (a derivative holding)SEC Form 46 June 2018Stock option (right to buy) · traded 4 June 2018 · filed 6 June 2018
- exercised options over 5,630 shares of Galectin Therapeutics (a derivative holding)SEC Form 46 June 2018Stock option (right to buy) · traded 5 June 2018 · filed 6 June 2018
- exercised options over 4,294 shares of Galectin Therapeutics (a derivative holding)SEC Form 46 June 2018Stock option (right to buy) · traded 5 June 2018 · filed 6 June 2018
- exercised options over 50,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 44 June 2018Stock option (right to buy) · traded 31 May 2018 · filed 4 June 2018
- exercised options over 9,500 shares of Galectin Therapeutics (a derivative holding)SEC Form 44 June 2018Stock option (right to buy) · traded 1 June 2018 · filed 4 June 2018
- exercised options over 59,700 shares of Galectin Therapeutics (a derivative holding)SEC Form 44 June 2018Stock option (right to buy) · traded 1 June 2018 · filed 4 June 2018
- exercised options over 50,000 shares of Galectin TherapeuticsSEC Form 44 June 2018Common Stock · traded 31 May 2018 · filed 4 June 2018
- ▼ sold on the open market 50,000 shares of Galectin TherapeuticsSEC Form 44 June 2018Common Stock · traded 31 May 2018 · filed 4 June 2018
- exercised options over 9,500 shares of Galectin TherapeuticsSEC Form 44 June 2018Common Stock · traded 1 June 2018 · filed 4 June 2018
- exercised options over 59,700 shares of Galectin TherapeuticsSEC Form 44 June 2018Common Stock · traded 1 June 2018 · filed 4 June 2018
- ▼ sold on the open market 69,200 shares of Galectin TherapeuticsSEC Form 44 June 2018Common Stock · traded 1 June 2018 · filed 4 June 2018
- was granted 90,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 424 May 2018Stock option (right to buy) · traded 22 May 2018 · filed 24 May 2018
- was granted 90,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 417 January 2018Stock option (right to buy) · traded 15 January 2018 · filed 17 January 2018
- was granted 150,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 46 December 2016Stock option (right to buy) · traded 3 December 2016 · filed 6 December 2016
- was granted 38,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 422 January 2016Stock option (right to buy) · traded 20 January 2016 · filed 22 January 2016
- was granted 38,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 42 February 2015Stock option (right to buy) · traded 29 January 2015 · filed 2 February 2015
- returned to the issuer 41,402 shares of Galectin TherapeuticsSEC Form 418 April 2014Common Stock · traded 16 April 2014 · filed 18 April 2014
- was granted 50,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 418 April 2014Stock Options · traded 16 April 2014 · filed 18 April 2014
- was granted 38,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 424 January 2014Stock Option (Right to Buy) · traded 21 January 2014 · filed 24 January 2014
- exercised options over 50,000 shares of Galectin TherapeuticsSEC Form 413 January 2014Common Stock · traded 10 January 2014 · filed 13 January 2014
- had shares withheld for tax on 8,598 shares of Galectin TherapeuticsSEC Form 413 January 2014Common Stock · traded 10 January 2014 · filed 13 January 2014
- exercised options over 50,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 413 January 2014Stock Options · traded 10 January 2014 · filed 13 January 2014
- ▲ bought on the open market 500 shares of Galectin TherapeuticsSEC Form 419 November 2013Common Stock · traded 18 November 2013 · filed 19 November 2013
- exercised options over 100,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 41 May 2013Stock Option (right to buy) · traded 29 April 2013 · filed 1 May 2013
- exercised options over 100,000 shares of Galectin TherapeuticsSEC Form 41 May 2013Common Stock · traded 29 April 2013 · filed 1 May 2013
- had shares withheld for tax on 46,586 shares of Galectin TherapeuticsSEC Form 41 May 2013Common Stock · traded 29 April 2013 · filed 1 May 2013
- was granted 250,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 429 August 2012Stock Options · traded 27 August 2012 · filed 29 August 2012
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.